Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Theravance - THRX -- Ignore unavailable to you. Want to Upgrade?

To: kenhott who wrote (55)	10/26/2007 10:27:57 AM
From: rkrw	Read Replies (1) \| Respond to of 74

Tough question. Usually you can best judge integrity in hindsight! :-) I think theravance is a decent company, I used to own it when it was more of a no brainer, i.e. when it was selling below the "put" price shareholders could sell to gsk for. I haven't yet listened to the thrx approvable call. But the pr said they thought they "may" not need new trials. May and the fda is always an iffy assumption as you know. But seeing mrsa in the media every single day makes me think maybe the fda will see this as an important drug to approve. Plus they have hospital acquired pneumonia data coming out soon that I think should be solid. Beyond Advair is the program with HR potential, but that's been going a bit slower than I would have liked and seeing gsk's performance with coreg cr makes me a little less optimistic that this is going to be an amazing $10B switch. The data will need to be supportive of superior efficacy and safety.